Background: Cerebral intra-arterial chemotherapy (CIAC) has been demonstrated to achieve tumoricidal concentrations in cerebral tumour cells that are otherwise unachievable due the presence of blood–brain barrier. In this study, we sought analyze safety CIAC a cohort patients treated at Centre intégré universitaire de santé et services sociaux l’Estrie—Centre hospitalier Sherbrooke (CIUSSS-CHUS). Methods: Treatments consisted monthly CIAC. A neurological examination and neuroimaging study...

Effectiveness of chemotherapy for treating glioblastoma (GBM) brain tumors is hampered by the blood-brain barrier which limits entry into most drugs from blood. To bypass this barrier, convection-enhanced delivery (CED) was proposed to directly inject in tumor. However, benefit CED may be when diffuse outside tumor then induce neurotoxicity. Encapsulation liposome aims at increasing cells specificity and reduces appropriate liposomal formulation still remains determined. In study, four...

Glioblastoma (GBM) represents the most common and aggressive malignant primary brain tumors in adults. Response to standard treatment is transitory survival of clinical trial cohorts are little more than 14 months. GBM characterized by excessive proliferation, invasiveness, radio-/chemoresistance features; which strongly upregulated transforming growth factor-beta (TGF-β). We hypothesized that TGF-β gene expression could correlate with overall (OS) serve as a prognostic biomarker. TGF-β₁ -β₂...

Abstract A typical cyclic heat treatment process has been adopted up to four cycles on initially annealed commercially pure aluminium, primarily containing iron impurity, that involves short‐duration (5 minutes) holding at 600 °C followed by ice‐brine quenching in each cycle. As a consequence, significant grain refinement effect and gradual accumulation of lattice strain during the progress are observed relation an evolution regions extremely low misorientation angle aluminium matrix. Apart...

Glioblastoma (GBM) is a difficult disease to treat for different reasons, with the blood–brain barrier (BBB) preventing therapeutic drugs from reaching tumor being one major hurdle. The median overall survival only 14.6 months after standard first line of treatment. At relapse, there no recognized second-line Our team uses intra-arterial (IA) chemotherapy as means bypass BBB, hence achieving an 25 months. However, most patients eventually fail treatment and progress. This why we wish expand...

High-grade gliomas (HGG) are aggressive brain tumors associated with short median patient survival and limited response to therapies, driving the need develop tools improve outcomes. Patient-derived xenograft (PDX) models, such as mouse PDX, have emerged potential Avatar platforms for personalized oncology approaches, but difficulty some human grafts grow successfully long time required mice preclude their use HGG.We used a rapid efficient ex-ovo chicken embryo chorioallantoic membrane (CAM)...

Abstract BACKGROUND Glioblastoma (GBM) is the most common and aggressive type of primary brain tumour in adults. The GBM malignant phenotype depicts anarchic invasion parenchyma as well radio-/chemoresistant properties. complete surgical resection unachievable responses to standard therapy are invariably transient. In addition phenotype, blood-brain barrier (BBB) one prominent features that limits efficacy chemotherapy. Indeed, this facet brain’s blood vessels significantly blocks passage...

Abstract BACKGROUND Being the most aggressive malignant primary brain tumor, glioblastoma (GBM) is a difficult disease to treat. The first line treatment consists in maximal resection followed by concomitant radiotherapy and temozolomide. However, patients will relapse during after treatment. overall survival only 14,6 months while progression-free 6,9 months. Even if first-line well established, there no consensus for second line. At our institution, Dr. Fortin prioritize intra-arterial...

Abstract Being the most aggressive malignant primary brain tumor, glioblastoma (GBM) is a difficult disease to treat. The first line treatment well established, but patients will relapse before or during treatments. overall survival only 14,6 months while progression-free 6,9 months. In Sherbrooke, Dr Fortin prioritize intra-arterial (IA) administration of chemotherapeutic agents (CTA) as second treatment. Unfortunately, certain not respond even develop chemoresistance agents. Therefore,...

Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumour in adults. Standard therapy, consisting surgery followed by concomitant radio- chemotherapy, only offers palliative benefits. Indeed, recurrence inevitable this disease remains incurable with an overall survival of 14.6 months. We believe that chemoresistant phenotype GBM supported their expression several efflux pumps (ABC transporters). thus hypothesized gene these transporters could correlate patients...

Abstract BACKGROUND Glioblastoma (GBM) is the most common and aggressive type of primary brain tumour in adults. These tumours depict anarchic proliferation infiltration as well radio- chemoresistant profiles. The complete surgical resection unachievable responses to standard therapy are transitory. Recurrence thus inevitable patient prognosis generally less than 15 months. Transforming growth factor-beta (TGF-β) holds a substantial role supporting GBM phenotype. We showed that TGF-β 1...

Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumour in adults. Response to standard therapy transitory, recurrence inevitable patients median overall survival inferior 15 months. The GBM phenotype characterized by anarchic proliferation invasiveness together with radio-/chemoresistance abilities. These features are strongly upregulated transforming growth factor-beta (TGF-b). Therefore, we hypothesized that TGF-b gene expression could correlate (OS) be...

Malignant glial tumors are associated with a poor prognosis, presenting short median patient survival and very limited response to therapies. Although the first line therapy is standardized, there exists no consensus as which second treatment modality better. We thus sought demonstrate feasibility of transforming our newly established expertise into personalized treatments for glioma patients by developing an advanced in vivo Avatar model developed from derived tumors. The typical medical...

Abstract Purpose Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumors in adults. Patients invariably relapse during or after first-line therapy median overall survival 14.6 months. Such poor clinical response partly ascribed to activity of ATP-binding cassette (ABC) transporters. The these proteins, severely reduces amount therapeutics that penetrates tumor cells. We hypothesized ABC transporter expression could correlate with surrogates. In this study, we...